A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 29 Aug 2019 Planned number of patients changed from 80 to 130.
- 12 Jun 2019 Planned End Date changed from 30 Apr 2020 to 25 Aug 2020.
- 12 Jun 2019 Planned primary completion date changed from 30 Oct 2020 to 25 Aug 2020.